Dupixent vs Pear Therapeutics

Dupixent vs Pear Therapeutics, compared side by side on 8 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Dupixent is on 6/100 and Pear Therapeutics on 49/100.

Dupixent logo
DupixentA biologic medicine developed by Sanofi and Regeneron Pharmaceuticals for treating various inflammatory conditions.
Try Dupixent
Pear TherapeuticsPioneered prescription digital therapeutics for serious diseases, integrating software with pharmaceuticals.
Try Pear Therapeutics

Where each one leads

Dupixent

  • agent readiness: 26/100 against 21/100

Pear Therapeutics

  • our overall score: 49/100 against 6/100

At a glance

MeasureDupixentPear Therapeutics
What it isA biologic medicine developed by Sanofi and Regeneron Pharmaceuticals for treating various inflammatory conditions.Pioneered prescription digital therapeutics for serious diseases, integrating software with pharmaceuticals.
CategoryHealthTech, AI Infrastructure, AI Tools, Generative AIHealthTech, MedTech, Biotech, Digital Therapeutics
Sells toBusiness modelB2BB2B
OfferingPlatformSoftware
FoundedNot published2013
HeadquartersNot publishedBoston, United States
StatusActiveInactive

Size, funding and growth

MeasureDupixentPear Therapeutics
Total fundingNot published$409M
Latest roundNot publishedPost-IPO Equity
ValuationNot published$1.6B

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureDupixentPear Therapeutics
StartupHub scoreOur 0-100 rating6/10049/100
TractionNot published40/100
TeamNot published70/100
Search visibilityNot published11/100
QualityNot published58/100
Agent readinessHow well an AI agent can read and act on the siteF (26/100)F (21/100)
Domain ratingLink authority, 0-100Not published54/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureDupixentPear Therapeutics
HostingNot detectedGoogle Cloud
Open sourceYesNo

Dupixent vs Pear Therapeutics: common questions

Which is better, Dupixent or Pear Therapeutics?

On our 0-100 score Pear Therapeutics rates higher (49/100 against 6/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 8 data points above: read the rows that match what you are buying for.

How do Dupixent and Pear Therapeutics compare on the numbers?

Dupixent leads on agent readiness (26/100 against 21/100). Pear Therapeutics leads on our overall score (49/100 against 6/100).

Read the full Dupixent review and pricing or the Pear Therapeutics review and pricing. You can also browse other Dupixent alternatives we track.